Status:
COMPLETED
Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
Lead Sponsor:
Latin American Cooperative Oncology Group
Collaborating Sponsors:
AstraZeneca
Conditions:
Lung Cancer, Non-small Cell
Eligibility:
All Genders
18+ years
Brief Summary
RELANCE is a large multi-institutional study that aims to retrospectively collect information about diagnostic, treatment and outcome of patients diagnosed with locally advanced NSCLC in Brazil. It is...
Detailed Description
RELANCE study will collect sociodemographic and clinical data of patients diagnosed with locally advanced NSCLC in the period of January 2015 and Jun 2019 in the participating institutions. Socio-demo...
Eligibility Criteria
Inclusion
- Patients aged 18 years or older;
- Histologically or cytological diagnosis of NSCLC in the period of January 2015 to December 2016;
- Locally Advanced NSCLC defined as clinical stage IIIA and IIIB according to 7th Edition TNM Staging System;
- Any NSCLC histological subtype and molecular mutation;
- Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
- Patients assigned by treating physician to any therapy or palliative care;
- Access to patient medical chart for data collection.
Exclusion
- Small cell lung cancer and non-invasive NSCLC;
- Synchronic NSCLC or second primary tumour in the last 5 years (except non-melanoma skin cancer).
Key Trial Info
Start Date :
September 25 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 9 2022
Estimated Enrollment :
403 Patients enrolled
Trial Details
Trial ID
NCT03836469
Start Date
September 25 2019
End Date
June 9 2022
Last Update
February 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AC Camargo
São Paulo, São Paulo, Brazil